$GEHC

GE HealthCare (GEHC) grants CFO options and 75K RSUs

GE HealthCare (GEHC) granted its CFO, William K. Grogan, 31,877 stock options with a $64.25 exercise price, expiring in 2036, and 75,096 restricted stock units (RSUs) on September 14, 2026. The RSUs vest in 2027-2029. No Rule 10b5-1 trading plan was reported.

Original reporting
Published Sep 16, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GEHC
Neutral
high confidence
Mentioned
$GEHC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GEHCNeutralLow
01

Why it matters

The compensation grant is routine and unlikely to move the stock.

02

Market read

Low relevance; typical insider grant with limited market effect.

03

What to watch

No Rule 10b5-1 plan; vesting schedule spreads impact over years.

Relevance 4/10Novelty 4/10Timing: post filing Sep 14 2026

Background

Form 4 filing reports equity compensation for GE HealthCare CFO.

Company-level read

Ticker impact

$GEHCNeutralHigh confidence
Context

SEC Form 4 disclosed the CFO received 31,877 stock options and 75,096 RSUs on Sep 14, 2026.

Expected impact

minimal to none

Evidence & confidence

The grant size is modest relative to market cap and no trading plan was filed.

Market effects

none

none

none

Counterpoint

The award could signal confidence in future performance, but size is too small to matter.

Key entities

  • William K. Grogan

    CFO of GE HealthCare

Related articles

$GEHCMedAI 8/10

GE HealthCare stock maintained at Buy by BTIG on imaging tech

BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.

$GEHCMedAI 8/10

GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?

GE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.

$GEHCHighAI 9/10

GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion

GE HealthCare is reportedly in advanced talks to acquire Sofie Biosciences for around $1 billion, according to the Financial Times. Sofie specializes in radiopharmaceuticals for PET imaging, which could expand GE HealthCare's diagnostics portfolio and create recurring revenue streams. The deal would mark GE HealthCare's second major acquisition since its 2023 separation from General Electric.

$GEHCHighAI 9/10

GE HealthCare Technologies in talks to buy Sofie Biosciences

GE HealthCare Technologies is in talks to acquire Sofie Biosciences for approximately $1 billion, according to the Financial Times. The deal, which could be announced next week, would be GE HealthCare's second major acquisition since its split from General Electric in 2024. Sofie specializes in radioactive chemicals used in cancer scans, and the acquisition would strengthen GE HealthCare's pharmaceutical diagnostics division.